Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T25127 |
Azalanstat
RS-21607,RS 21607,RS21607 |
||
Azalanstat is a lanosterol 14 alpha-demethylase inhibitor. The enzyme catalyzes the first step in the conversion of lanosterol to cholesterol in mammals. | |||
T70660 |
Azalanstat HCl
|
||
Azalanstat HCl is an anti-obesity drug acting as a lanosterol 14α-demethylase inhibitor. Azalanstat HCl has been shown to inhibit cholesterol synthesis in HepG2 cells, human fibroblasts, hamster hepatocytes and hamster liver, by inhibiting the cytochrome P450 enzyme lanosterol 14 alpha-demethylase. When administered orally to hamsters fed regular chow, RS-21607 (50 mg/kg/day) lowered serum cholesterol in a dose-dependent manner (ED50 = 62 mg/kg) in a period of 1 week. It preferentially lowered l... | |||
T70661 |
Azalanstat mesylate
|
||
Azalanstat mesylate is an anti-obesity drug acting as a lanosterol 14α-demethylase inhibitor. Azalanstat mesylate has been shown to inhibit cholesterol synthesis in HepG2 cells, human fibroblasts, hamster hepatocytes and hamster liver, by inhibiting the cytochrome P450 enzyme lanosterol 14 alpha-demethylase. When administered orally to hamsters fed regular chow, RS-21607 (50 mg/kg/day) lowered serum cholesterol in a dose-dependent manner (ED50 = 62 mg/kg) in a period of 1 week. It preferentially... | |||
T70659 | BR103 | ||
BR103 is a C3aR-selective agonist that is metabolically stable. | |||
T70658 |
Ici D8731
|
||
Ici D8731 is a nonpeptide angiotensin II antagonist with potential as a treatment for hypertension and heart failure. |